3rd Quarter - Report

I AM ALS for I AM ALS

Firm
Client
Income
—
Expenses
$20,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

ALS treatment and research funding within FY26 Labor, Health and Human Services, Education and Related Agencies appropriations bill (S.2587) including ACT for ALS and ARPA-H. ALS research funding within the FY26 Defense appropriations bill (S.2572 / H.R.4016)for the Congressional Directed Medical Research Program's ALS Research Program. ALS treatment and research funding for ALS within the FY26 Agriculture, Food and Drug Administration, and Related Agencies appropriations bill (S.2256 / H.R.4121).

LobbyistCovered position, as disclosed
DUSTIN WATSON —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Defense, Dept of (DOD)

Bills named: S. 2587 (119th), H.R. 4121 (119th), S. 2256 (119th), S. 2572 (119th), H.R. 4016 (119th)

Defense DEF

FY26 Defense appropriations bill (S.2572 / H.R.4016) for Congressional Directed Medical Research Program's ALS Research Program.

LobbyistCovered position, as disclosed
DUSTIN WATSON —

Contacted: Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2572 (119th), H.R. 4016 (119th)

Health Issues HCR

Reauthorization and fully funding of the ACT for ALS (Public Law 117-79) for continued access to promising treatments and research. (S.925/H.R.2036) Credit for Caring Act to provide relief in the form of a new, non-refundable federal tax credit for eligible working family caregivers. (S.1261) The CONNECT for Health Act to expand coverage of telehealth services through Medicare and make it easier for ALS patients to connect with their doctors. Regulatory flexibility at FDA for expedited pathways to promising treatments for ALS patients because the standard drug approval process (12-14 years) takes too long for people with rapidly progressive terminal conditions with no substantial therapies.

LobbyistCovered position, as disclosed
DUSTIN WATSON —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 2036 (119th), S. 1261 (119th), S. 925 (119th)

Veterans VET

(S.749 / H.R.1685) Justice for ALS Veterans Act to extend dependency and indemnity compensation (DIC) benefits to surviving spouses of Veterans who die from ALS, regardless of how long the Veteran lived with the disease.

LobbyistCovered position, as disclosed
DUSTIN WATSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 749 (119th), H.R. 1685 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.